$1,170,000 of TENET HEALTHCARE CORPORATION lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Hospital and physician payments under Medicare and Medicaid, general. Medicare/ Medicaid Reform- (Bundling of Medicare acute and post-acute hospital payments, payments for readmissions, value-based purchasing, physician self-referral)- Implementation of the Health Care and Education Reconciliation Act of 2012 (Pub. Law 111-143). Medicare site neutral payments Federal exchange subsidies under The Affordable Care Act Medicare and Medicaid Disproportionate Share Hospital funding Accountable Care Organization (ACO) programs CHGME ACA Stabilization Price Transparency Telehealth 340B Medicare payment policy: IPPS/OPPS Graduate Medical Education (GME) Outpatient Surgery Quality and Access Act Medicaid Fiscal Accountability Regulation (MFAR) ACA premium tax credits Hospital and physician payments under Medicare and Medicaid, general. Medicare/ Medicaid Reform- (Bundling of Medicare acute and post-acute hospital payments, payments for readmissions, value-based purchasing, physician self-referral)- Implementation of the Health Care and Education Reconciliation Act of 2012 (Pub. Law 111-143). Medicare site neutral payments Federal exchange subsidies under The Affordable Care Act Medicare and Medicaid Disproportionate Share Hospital funding Accountable Care Organization (ACO) programs CHGME ACA Stabilization Price Transparency Telehealth 340B Medicare payment policy: IPPS/OPPS Graduate Medical Education (GME) Outpatient Surgery Quality and Access Act Medicaid Fiscal Accountability Regulation (MFAR) ACA premium tax credits House and Senate Budgets as pertain to Medicare and Medicaid. Consumer Financial Protection Bureau Rulemaking Tax Reform FTC non-compete rulemaking"
You can find more data on corporate lobbying on Quiver Quantitative.
THC Congressional Stock Trading
Members of Congress have traded $THC stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $THC stock by members of Congress over the last 6 months:
- REPRESENTATIVE JONATHAN L. JACKSON has traded it 2 times. They made 1 purchase worth up to $50,000 on 12/10 and 1 sale worth up to $15,000 on 02/11.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
THC Insider Trading Activity
THC insiders have traded $THC stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $THC stock by insiders over the last 6 months:
- THOMAS W ARNST (EVP, Chief Admin. Officer & GC) has made 0 purchases and 3 sales selling 32,000 shares for an estimated $7,527,737.
- TAMMY ROMO has made 0 purchases and 6 sales selling 27,500 shares for an estimated $5,563,324.
- R. SCOTT RAMSEY (Principal Accounting Officer) has made 0 purchases and 6 sales selling 21,339 shares for an estimated $4,598,015.
- PAOLA M ARBOUR (EVP, Chief Information Officer) sold 6,500 shares for an estimated $1,549,795
- RICHARD W FISHER sold 2,500 shares for an estimated $521,075
- NADJA WEST sold 2,178 shares for an estimated $430,089
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
THC Hedge Fund Activity
We have seen 333 institutional investors add shares of THC stock to their portfolio, and 327 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- LONE PINE CAPITAL LLC added 1,787,326 shares (+inf%) to their portfolio in Q4 2025, for an estimated $355,177,422
- WELLINGTON MANAGEMENT GROUP LLP added 1,042,260 shares (+1114.2%) to their portfolio in Q4 2025, for an estimated $207,117,907
- CITADEL ADVISORS LLC removed 1,020,474 shares (-96.7%) from their portfolio in Q4 2025, for an estimated $202,788,593
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 692,708 shares (-75.8%) from their portfolio in Q4 2025, for an estimated $137,654,933
- PACER ADVISORS, INC. removed 538,299 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $106,970,777
- MILLENNIUM MANAGEMENT LLC removed 529,280 shares (-71.1%) from their portfolio in Q4 2025, for an estimated $105,178,521
- EMINENCE CAPITAL, LP removed 495,489 shares (-44.7%) from their portfolio in Q4 2025, for an estimated $98,463,574
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
THC Analyst Ratings
Wall Street analysts have issued reports on $THC in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 01/07/2026
- Barclays issued a "Overweight" rating on 11/21/2025
- JP Morgan issued a "Overweight" rating on 11/13/2025
- RBC Capital issued a "Outperform" rating on 10/30/2025
- Cantor Fitzgerald issued a "Overweight" rating on 10/29/2025
- Guggenheim issued a "Buy" rating on 10/29/2025
- UBS issued a "Buy" rating on 10/29/2025
To track analyst ratings and price targets for THC, check out Quiver Quantitative's $THC forecast page.
THC Price Targets
Multiple analysts have issued price targets for $THC recently. We have seen 13 analysts offer price targets for $THC in the last 6 months, with a median target of $264.0.
Here are some recent targets:
- Jason Cassorla from Guggenheim set a target price of $283.0 on 03/12/2026
- Ann Hynes from Mizuho set a target price of $265.0 on 03/12/2026
- Whit Mayo from Leerink Partners set a target price of $264.0 on 02/20/2026
- David Macdonald from Truist Securities set a target price of $270.0 on 02/17/2026
- Andrew Mok from Barclays set a target price of $257.0 on 02/13/2026
- Matthew Gillmor from Keybanc set a target price of $250.0 on 02/12/2026
- A.J. Rice from UBS set a target price of $288.0 on 02/12/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
